ArticleOpen forum infectious diseases2026
Refractory Mucocutaneous Infections by Herpes Simplex Virus (HSV) in Hematopoietic Cell Transplant Recipients: A Real-world, Multicenter Study.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Background: We examined treatment patterns and clinical outcomes of adult hematopoietic cell transplant (HCT) recipients with refractory mucocutaneous herpes simplex virus (HSV) infection from 7 US centers. Methods: Multicenter, retrospective study of laboratory confirmed HSV infection and failure to improve after ≥7 days of appropriately dosed anti-HSV therapies. Resistance testing was performed at clinicians' discretion. Therapies were captured for the first refractory HSV infection post-HCT (index episode). Time to complete lesion healing, toxicities, and HSV recurrence up to 1 year from index HSV episode lesion healing were extracted from electronic medical records. The cumulative incidence function was used to estimate time to healing with death as competing risk. Results: Of 125 patients, acyclovir resistance was confirmed in 85/104 patients (81.7%) tested. First therapy was nucleoside analog in 100 patients and foscarnet in 25. A total of 110 patients (88%) received second line therapy(ies), including foscarnet (94), intravenous cidofovir (6), and/or topical antivirals (21). Mean treatment durations (SD) were 21.8 days (13.8), 20.3 (10.1), and 41.0 (37.5) for foscarnet, cidofovir, and topicals, respectively. Complete healing occurred in 69 patients (55.2%) at a median of 38 days (range 257) from the anti-HSV therapy start. Nephrotoxicity was reported during 40.4% of foscarnet and 50.0% of cidofovir courses, respectively. Among 69 patients with completed healing, 27 (39.1%) experienced HSV recurrence during follow up. Conclusions: Our study highlights the challenges of managing refractory HSV post-HCT during the study timeframe, and underscores the unmet need for safer, more effective, and orally bioavailable therapies for refractory HSV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.